Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Luis Lopez-Lazaro"'
Autor:
Auro Viswabandya, Sandip Shah, Asis Mukhopadhyay, Rajnish Vasant Nagarkar, Sonica Sachdeva Batra, Luis Lopez-Lazaro, Suresh Kankanwadi, Alok Srivastava
Publikováno v:
Journal of Global Oncology, Vol 5, Pp 1-13 (2019)
PURPOSE: We sought to compare the pharmacokinetics (PKs) of DRL-rituximab (DRL_RI; potential biosimilar) and innovator rituximab MabThera (Roche, Grenzach-Wyhlen, Germany; reference medicinal product [RMP]) in patients with diffuse large B-cell lymph
Externí odkaz:
https://doaj.org/article/a5b501abbb974e8e9cf326f59bb9eec6
Autor:
Vikram Muralidhar Haridas, Luis Lopez-Lazaro, Rahul Katta, Sandeep V. Kharkar, Sonica Sachdeva Batra, Olena Garmish, Suresh Kankanwadi, Vyacheslav Zhdan, Ajit Nalawade
Publikováno v:
Biodrugs
Objectives The aims were to demonstrate pharmacokinetic (PK) similarity between DRL_RI, a proposed rituximab biosimilar, and two reference innovator products (Rituxan® [RTX-US] and MabThera® [RTX-EU]) and compare their pharmacodynamics (PD), effica
Autor:
Sonica Sachdeva Batra, Suresh Kankanwadi, A. Mukhopadhyay, Auro Viswabandya, Sandip Shah, Luis Lopez-Lazaro, Rajnish Vasant Nagarkar, Alok Srivastava
Publikováno v:
Journal of Global Oncology
Journal of Global Oncology, Vol 5, Pp 1-13 (2019)
Journal of Global Oncology, Vol 5, Pp 1-13 (2019)
PURPOSE We sought to compare the pharmacokinetics (PKs) of DRL-rituximab (DRL_RI; potential biosimilar) and innovator rituximab MabThera (Roche, Grenzach-Wyhlen, Germany; reference medicinal product [RMP]) in patients with diffuse large B-cell lympho
Publikováno v:
British Journal of Clinical Pharmacology. 84:2352-2364
Aim The aim of this study was to compare the pharmacokinetics (PK) of DRL_BZ with that of EU-approved (reference medicinal product; RMP) and US-licensed (reference product; RP) bevacizumab (Avastin® ) in healthy male subjects. Methods In this double
Autor:
Suresh Kankanwadi, Chayan Acharya, Andrew C. Hooker, Gunnar Yngman, Elodie L. Plan, Luis Lopez-Lazaro, Ari Brekkan, Mats O. Karlsson
Neutropenia and febrile neutropenia (FN) are serious side effects of cytotoxic chemotherapy which may be alleviated with the administration of recombinant granulocyte colony-stimulating factor (GCSF) derivatives, such as pegfilgrastim (PG) which incr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c2c17ab578916a46c2d03e67524a351
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-362482
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-362482
Autor:
Luis Lopez-Lazaro, Stephan Duparc, Jangsik Shin, Rolf Pokorny, Robert M Miller, Lawrence Fleckenstein, Isabelle Borghini-Fuhrer, Carrie A. Morris, Sarah Arbe-Barnes
Publikováno v:
Antimicrobial Agents and Chemotherapy
The objectives of this study were to characterize any drug-drug interaction between the antimalarial Pyramax (pyronaridine-artesunate [PA]) and the CYP2D6 probe substrate metoprolol and to assess the safety of 60-day or 90-day PA redosing, particular
Autor:
Peter N. Lohstroh, Donald Jung, Luis Lopez-Lazaro, Stephen R. Dueker, Lawrence Fleckenstein, Xin-Ping Fang, Mark Baker, Jangsik Shin, Carrie A. Morris, Li-Quan Wang, Rolf Pokorny, Stephan Duparc, Isabelle Borghini-Fuhrer
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 40:75-86
This was a single dose mass balance and metabolite characterization study of the antimalarial agent pyronaridine. Six healthy male adults were administered a single oral dose of 720 mg pyronaridine tetraphosphate with 800 nCi of radiolabeled (14)C-py
Autor:
Janthima Methaneethorn, Luis Lopez-Lazaro, Lawrence Fleckenstein, Isabelle Borghini-Fuhrer, Carrie A. Morris, Stephan Duparc, Chang-Sik Shin, Rolf Pokorny, Donald Jung
Publikováno v:
The American Journal of Tropical Medicine and Hygiene
A multiple dose, parallel group study was conducted to assess for a drug-drug interaction between the pyronaridine/artesunate (PA) combination antimalarial and ritonavir. Thirty-four healthy adults were randomized (1:1) to receive PA for 3 days or PA
Publikováno v:
Biology of Blood and Marrow Transplantation. 15(3):336-343
Buccal administration of budesonide (mouthwash) may be effective as a topical add-on therapy in patients with oral chronic graft-versus-host disease (cGVHD). Safety of approved oral budesonide is based on high intestinal and hepatic extraction by cyt
Autor:
Luis Lopez-Lazaro, Olaf van Tellingen, Jos H. Beijnen, Jan H.M. Schellens, Jan Handrick Beumer
Publikováno v:
Current Clinical Pharmacology. 4:38-42
Trabectedin (ET-743, Yondelis™) is a novel anticancer drug with impressive activity in soft tissue sarcoma with a manageable, non-cumulative toxicity profile. Protein binding can be a major determinant of unbound concentration, volume of distributi